How important is gametocyte clearance after malaria therapy?
Identifieur interne : 001C96 ( PubMed/Corpus ); précédent : 001C95; suivant : 001C97How important is gametocyte clearance after malaria therapy?
Auteurs : Harin A. Karunajeewa ; Ivo MuellerSource :
- BMC medicine [ 1741-7015 ] ; 2016.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antimalarials, Artemisinins.
- drug effects : Plasmodium falciparum.
- drug therapy : Malaria, Falciparum.
- epidemiology : Malaria, Falciparum.
- parasitology : Culicidae.
- transmission : Malaria, Falciparum.
- Animals, Humans.
Abstract
There has been increasing interest in the role of malaria drugs in preventing malaria transmission from humans to mosquitoes, which would help augment malaria control and elimination strategies. Nevertheless, only one stage in the malaria parasite life cycle, the gametocyte, is infectious to mosquitoes. The Worldwide Antimalarial Resistance Network (WWARN) have analyzed data from 48,840 patients from 141 clinical trials in order to define the nature and determinants of gametocyte clearance following artemisinin combination treatment (ACT) for symptomatic malaria infections. However, the presence of gametocytes does not always predict their infectivity, meaning that the microscopy-based methods used by the WWARN investigators represent an imperfect surrogate marker of transmissibility. Their findings, that some ACTs clear gametocytes faster than others, should be interpreted in light of these limitations and important gaps in our understanding of the biology and epidemiology of malaria transmission.Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0621-7.
DOI: 10.1186/s12916-016-0641-3
PubMed: 27317420
Links to Exploration step
pubmed:27317420Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">How important is gametocyte clearance after malaria therapy?</title>
<author><name sortKey="Karunajeewa, Harin A" sort="Karunajeewa, Harin A" uniqKey="Karunajeewa H" first="Harin A" last="Karunajeewa">Harin A. Karunajeewa</name>
<affiliation><nlm:affiliation>Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Vic, 3052, Australia. karunajeewa.h@wehi.edu.au.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mueller, Ivo" sort="Mueller, Ivo" uniqKey="Mueller I" first="Ivo" last="Mueller">Ivo Mueller</name>
<affiliation><nlm:affiliation>Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Vic, 3052, Australia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27317420</idno>
<idno type="pmid">27317420</idno>
<idno type="doi">10.1186/s12916-016-0641-3</idno>
<idno type="wicri:Area/PubMed/Corpus">001C96</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C96</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">How important is gametocyte clearance after malaria therapy?</title>
<author><name sortKey="Karunajeewa, Harin A" sort="Karunajeewa, Harin A" uniqKey="Karunajeewa H" first="Harin A" last="Karunajeewa">Harin A. Karunajeewa</name>
<affiliation><nlm:affiliation>Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Vic, 3052, Australia. karunajeewa.h@wehi.edu.au.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Mueller, Ivo" sort="Mueller, Ivo" uniqKey="Mueller I" first="Ivo" last="Mueller">Ivo Mueller</name>
<affiliation><nlm:affiliation>Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Vic, 3052, Australia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC medicine</title>
<idno type="eISSN">1741-7015</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antimalarials (therapeutic use)</term>
<term>Artemisinins (therapeutic use)</term>
<term>Culicidae (parasitology)</term>
<term>Humans</term>
<term>Malaria, Falciparum (drug therapy)</term>
<term>Malaria, Falciparum (epidemiology)</term>
<term>Malaria, Falciparum (transmission)</term>
<term>Plasmodium falciparum (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term>
<term>Artemisinins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Plasmodium falciparum</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Malaria, Falciparum</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Malaria, Falciparum</term>
</keywords>
<keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Culicidae</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Malaria, Falciparum</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There has been increasing interest in the role of malaria drugs in preventing malaria transmission from humans to mosquitoes, which would help augment malaria control and elimination strategies. Nevertheless, only one stage in the malaria parasite life cycle, the gametocyte, is infectious to mosquitoes. The Worldwide Antimalarial Resistance Network (WWARN) have analyzed data from 48,840 patients from 141 clinical trials in order to define the nature and determinants of gametocyte clearance following artemisinin combination treatment (ACT) for symptomatic malaria infections. However, the presence of gametocytes does not always predict their infectivity, meaning that the microscopy-based methods used by the WWARN investigators represent an imperfect surrogate marker of transmissibility. Their findings, that some ACTs clear gametocytes faster than others, should be interpreted in light of these limitations and important gaps in our understanding of the biology and epidemiology of malaria transmission.Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0621-7.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27317420</PMID>
<DateCreated><Year>2016</Year>
<Month>06</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>11</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<PubDate><Year>2016</Year>
<Month>Jun</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>BMC medicine</Title>
<ISOAbbreviation>BMC Med</ISOAbbreviation>
</Journal>
<ArticleTitle>How important is gametocyte clearance after malaria therapy?</ArticleTitle>
<Pagination><MedlinePgn>93</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-016-0641-3</ELocationID>
<Abstract><AbstractText>There has been increasing interest in the role of malaria drugs in preventing malaria transmission from humans to mosquitoes, which would help augment malaria control and elimination strategies. Nevertheless, only one stage in the malaria parasite life cycle, the gametocyte, is infectious to mosquitoes. The Worldwide Antimalarial Resistance Network (WWARN) have analyzed data from 48,840 patients from 141 clinical trials in order to define the nature and determinants of gametocyte clearance following artemisinin combination treatment (ACT) for symptomatic malaria infections. However, the presence of gametocytes does not always predict their infectivity, meaning that the microscopy-based methods used by the WWARN investigators represent an imperfect surrogate marker of transmissibility. Their findings, that some ACTs clear gametocytes faster than others, should be interpreted in light of these limitations and important gaps in our understanding of the biology and epidemiology of malaria transmission.Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0621-7.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karunajeewa</LastName>
<ForeName>Harin A</ForeName>
<Initials>HA</Initials>
<AffiliationInfo><Affiliation>Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Vic, 3052, Australia. karunajeewa.h@wehi.edu.au.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Western Centre for Health Research and Education, Western Health, Melbourne, Australia. karunajeewa.h@wehi.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mueller</LastName>
<ForeName>Ivo</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Vic, 3052, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Malaria: Parasites & Hosts Unit, Institut Pasteur, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>06</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Med</MedlineTA>
<NlmUniqueID>101190723</NlmUniqueID>
<ISSNLinking>1741-7015</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9RMU91N5K2</RegistryNumber>
<NameOfSubstance UI="C031327">artemisinine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mol Biochem Parasitol. 2005 Sep;143(1):67-79</RefSource>
<PMID Version="1">16005087</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Malar J. 2014 Dec 09;13:483</RefSource>
<PMID Version="1">25486998</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2014 Jun 30;(6):CD008152</RefSource>
<PMID Version="1">24979199</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Med. 2016 Mar 08;14:40</RefSource>
<PMID Version="1">26952094</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Parasitol. 2010 Aug 15;40(10):1221-8</RefSource>
<PMID Version="1">20515695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2013 Feb;13(2):175-81</RefSource>
<PMID Version="1">23182932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Comput Biol. 2014 Jan;10(1):e1003434</RefSource>
<PMID Version="1">24465196</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2011 Jan 25;8(1):e1000402</RefSource>
<PMID Version="1">21311580</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Parasitol. 2010 Aug 15;40(10):1213-20</RefSource>
<PMID Version="1">20460125</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Med. 2016 May 24;14 :79</RefSource>
<PMID Version="1">27221542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2012 Feb;9(2):e1001169</RefSource>
<PMID Version="1">22363211</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009033" MajorTopicYN="N">Culicidae</DescriptorName>
<QualifierName UI="Q000469" MajorTopicYN="Y">parasitology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016778" MajorTopicYN="N">Malaria, Falciparum</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010963" MajorTopicYN="N">Plasmodium falciparum</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4912799</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antimalarial</Keyword>
<Keyword MajorTopicYN="N">Artemisinin combination therapy</Keyword>
<Keyword MajorTopicYN="N">Gametocyte clearance</Keyword>
<Keyword MajorTopicYN="N">Gametocytes</Keyword>
<Keyword MajorTopicYN="N">Malaria</Keyword>
<Keyword MajorTopicYN="N">P. falciparum</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>06</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>06</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27317420</ArticleId>
<ArticleId IdType="doi">10.1186/s12916-016-0641-3</ArticleId>
<ArticleId IdType="pii">10.1186/s12916-016-0641-3</ArticleId>
<ArticleId IdType="pmc">PMC4912799</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001C96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:27317420 |texte= How important is gametocyte clearance after malaria therapy? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27317420" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |